Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial of the Adenosine 2a Antagonist SYN115 in Parkinson Disease
Movement Disorders
(-)
001
Authors/Disclosures
Kevin Black, MD (Washingon University School of Medicine) No disclosure on file
Joel Salinas, MD, MBA, MSc, FAAN (NYU Langone Health) Dr. Salinas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai, Inc. Dr. Salinas has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly, Inc. Dr. Salinas has stock in Isaac Health.
Meghan C. Campbell, PhD (Washington University in St. Louis) The institution of Meghan C. Campbell has received research support from NIH. The institution of Meghan C. Campbell has received research support from NIH. The institution of Meghan C. Campbell has received research support from McDonnell Center for Systems Neuroscience. The institution of Meghan C. Campbell has received research support from WUSM Radiology Department. The institution of Meghan C. Campbell has received research support from NIH. Meghan C. Campbell has received personal compensation in the range of $0-$499 for serving as a Grant Reviewer with Parkinson Foundation. Meghan C. Campbell has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Department of Defense.
No disclosure on file
Wissam G. Deeb, MD (UMass Memorial) Dr. Deeb has a non-compensated relationship as a Board member with Davis Phinney Foundation that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
Stephen I. Bandak, MBBS, MRCP (Synosia Therapeutics) No disclosure on file